Table of Contents
Volume 2010, Article ID 280731, 9 pages
Review Article

New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty

Department of Orthopaedic Surgery, Roper Hospital, Charleston Orthopaedic Associates, 1012 Physicians Drive, Charleston, SC 29414, USA

Received 16 March 2010; Revised 28 May 2010; Accepted 6 June 2010

Academic Editor: Gualtiero Palareti

Copyright © 2010 Richard J. Friedman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Anticoagulant drugs reduce the risk of venous thromboembolic events after total hip and knee arthroplasty. However, the use of current drugs, such as low molecular weight heparins, is hampered by their subcutaneous route of administration. The use of vitamin K antagonists is hampered by the requirement for routine coagulation monitoring and dose titration to provide effective anticoagulation without an increased risk of bleeding and numerous food and drug interactions. Clearly, there is a need for new oral, fixed-dose anticoagulant drugs that do not require coagulation monitoring, while demonstrating similar or better efficacy and safety profiles when compared with current agents.